PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lac...
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and ...
The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetri...
OSAKA, Japan & CAMBRIDGE, Mass., June 03, 2025--Takeda (TSE:4502/NYSE:TAK) today announced that the ...
DUBLIN--(BUSINESS WIRE)--The "Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, ...